In a previous study of 10 drug-naive schizo phrenic patients, the density of D2 dopamine receptors was found to be elevated in the caudate nucleus. The study raised questionse about the influence of the age of the pa tients, the relationship of receptor density to psychosis, and the accuracy of the method used to obtain this evidence. Using positron emission tomography and constrained anal ysis of the brain uptake of the radioligand N-[IIC]methyl spiperone ([llC]NMSP), we tested four questions: Were the assumptions underlying the quantitation valid? Is there an age decline of the density of D2-like dopamine receptors in drug-naive schizophrenia and bipolar illness? If so, is it different from that observed in normal aging? Are Dz-like dopamine receptors elevated at any age in either drug naive schizophrenic or psychotic bipolar illness patients?
In 1986 we reported a twofold elevation of the D2 dopamine receptor density (Emax) in the caudate nucleus of 10 patients with untreated schizophrenia compared with age-matched normal volunteers (Wong et aI., 1986c) . The method used to obtain this tein fractions were not significantly different among patient groups and normal volunteers. The model-derived assay of radioligand metabolites in plasma was confirmed by high-performance liquid chromatography in the patient groups. D2-like dopamine receptors declined with age, and the slope did not differ significantly between the schizo phrenic patients, bipolar affective illness patients, and nor result was a modified Woolf-Hanes plot (Cressie and Keightly, 1981) , which included two determina tions of the distribution of [IIC]N-methylspiperone ([IIC]NMSP) at a h i gh spec i fic act i v i ty i n the bra i n, with the second determination conducted after ad ministration of a dose of haloperidol sufficient to block a number of D2 dopamine receptors (Wong et aI., 1986a (Wong et aI., ,b, 1997 Gjedde and Wong, 1990) . The significant elevation of D2 receptor density in schizophrenia was not confirmed in two studies of [1IC]raclopride binding (Farde et aI., 1990; Hietala et aI., 1994) . The lack of a difference between patients and controls also agreed with the originally negative findings of Wong et a1. (1985) and Martinot et a1. (1990) , both of which were based on the simple ratio between radioactivity in the caudate nucleus and the cerebellum after injection of radiolabeled spiper one analogs.
Using either the ratio (Wong et aI., 1984) or the actual calculation of receptor Bmax (Wong et aI., 1997) , we demonstrated that D2-like dopamine recep tors decline with age. The decline in normal aging raises four questions: 1) Are the assumptions under lying the modified Woolf-Hanes plot valid for studies of psychosis? 2) Does the receptor decline with age also occur in psychosis, especially in schizophrenia and bipolar illness? 3) If so, is the decline different from that observed in normal aging? 4) Are Drlike dopamine receptors elevated in drug-naive schizo phrenic patients and in psychotic disorders other than schizophrenia when the effect of aging is considered?
In this paper, we answer these questions. We test in vivo the hypothesis that [llC]NMSP binding is ele vated in the two psychotic disorders, bipolar illness and schizophrenia, when aging effects are considered. The assumptions underlying the method were tested separately by measuring partition volumes and plasma protein binding fractions of haloperidol and NMSP in postmortem and in vivo psychotic subjects and by comparing the kinetically determined in vivo metabolites of [lIC]NMSP with high-pressure liquid chromatogr'lphy (HPLC) measurements. The second and third questions were addressed by determining the D2 dopamine receptor density in the caudate nu cleus as a function of age in several patient groups, including those with another psychotic disorder, bi polar affective illness.
Recently, Seeman et ai. (1993) showed that spiper one and its derivatives may bind to dopamine D3 and D4 receptors in addition to D2 sites, whereas raclopride binds to D2 and D3 sites only. For the binding of [lJC]NMSP, a spiperone derivative, the term D2-like has been applied to the combined group of D2, D3, and D4 receptors. Elevated receptor den sity in psychosis, as measured by [II C]NMSP, is espe cially relevant because it has been hypothesized that D4 is the receptor subgroup that is elevated in schizo phrenia (Seeman et aI., 1993) .
ASSUMPTIONS

Calculation of Bmax
The dopamine D2 receptor density Bmax was calcu lated by means of a modified Woolf-Hanes plot as described by Wong et ai. (1997) :
where t1t is the difference between the time constants of binding in the presence and absence of a competi- tor (e.g., haloperidol) when the time constants are the reciprocal of the values of k3, the forward binding rate to the receptor; CH is the steady-state plasma haloperidol concentration; and Dw is a lumped coef ficient equal to the ratio (Wong et aI., 1997) ,
where I I and Kr refer to the unlabeled inhibitor (e.g., haloperidol) and k�n and Vd' refer to the labeled radiotracer NMSP. In this paper, it is assumed that the binding coefficient Dw is the same in patients and normal volunteers. This assumption was tested by evaluating the components that constitute the lumped coefficient. Because Dw is a lumped coeffi cient, the assumption is valid when the constituents are constant across subject groups. It is necessary to determine accurately the labeled metabolites of [IIC]NMSP in plasma.
METHODS
Validation of assumptions
In vitro studies. To test the key assumptions under lying the quantitative procedure, we (1) determined the partition volume for haloperidol and NMSP, and (2) confirmed the kinetic correction for NMSP me tabolites by HPLC. We tested whether the partition volume of haloperidol in the region of interest was the same in postmortem tissue from patients with schizophrenia and bipolar illness and from normal controls. The numerator of Dw was calculated by determining the free fraction of haloperidol (f l ) in plasma from subjects in the three groups.
1. Partition volume: To determine the distribution volume, Vd', for NMSP, we measured the free frac tion of [llC]NMSP in plasma it and the partition volume of [llC]NMSP V* where V* = 1* V* To e , e I d' compare the brain-to-blood partition volume for haloperidol in patients, we determined the haloperi dol brain-to-blood partition volume in cerebellum from control subjects, patients with schizophrenia, and patients with bipolar disease.
[lSF]haloperidol with a specific activity of 1-2 jLCi pmol-I was produced by the method of Shiue et ai. (1989) . Cerebellum tissue was obtained at autopsy from seven normal subjects (mean age, 38 :± 21 years SD; four males and three females), six schizophrenic subjects (37 :± 16 years; five males, and one female), and six patients with bipolar disease (47 :± 20 years; one male and five females). Tissue was stored at -80°C (interval from death to tissue freezing less than 24 h). The cerebellar tissue was thawed to waxy consistency and dissected into tissue prisms (0.5 mm). The tissue then was suspended (25 mg ml-I) in fresh human plasma containing a <T-receptor blocker, d-pentazocine (50 nM). [18F]haloperidol (5 nM) was added to triplicate samples and incu bated at 37°C for 60 min as described by Wong et ai. (1997) .
2. Plasma protein binding ([ I and fn The presence of plasma proteins may influence the blood partition ing of haloperidol in vivo. To determine the free fractionJI for haloperidol andfi for NMSP, we mea sured their protein binding in plasma. Thus, plasma protein binding of [1lC]NMSP and [18F]haloperidol in the different diagnostic groups (bipolar disorder and schizophrenia) was determined as described by Wong et ai. (1997) .
3. Plasma metabolites: To test the validity of the kinetic method of metabolite correction across the diagnostic groups in humans, we analyzed plasma samples for metabolites of [I I C]NMSP with HPLC (Wong et ai., 1997) . Metabolite analysis included four normal volunteers (Wong et ai., 1997) , eight patients with schizophrenia, and two patients with bipolar disorder, with as many as six blood samples per posi tron emission tomography (PET) study for a total of 127 samples from 23 studies. The metabolite data obtained usiij.g HPLC was compared with the kinetic metabolite correction data (Wong et ai., 1986a) for each diagnostic group.
In vivo studies. To examine the effects of aging in psychosis, we measured the D2-like dopamine recep tor density (Bmax) in patients with bipolar affective illness and in neuroleptic-naive patients with schizo phrenia. We examined 14 patients with bipolar disor der (11 manic and three depressed at the time of study) and 22 patients with schizophrenia (10 of whom were previously presented in Wong et ai., 1986c) . All subjects gave informed consent in compli ance with The Johns Hopkins Joint Committee on Clinical Investigation.
All patients satisfied the Diagnostic and Statistical Manual of Mental Disorders (DSM)IIIR criteria for bipolar disorder or schizophrenia. Patients were ex cluded if they had a history of a head injury leading to unconsciousness greater than 1 h; weight loss >25% of their body weight in the past 6 months; amphetamine or cocaine use in the past year; a history of seizures, dementia, or any other CNS disease; men tal retardation; or alcohol, drug, or steroid use. All patients with schizophrenia were neuroleptic naive, as were 11 patients with bipolar disorder. The three remaining bipolar patients were medication free for at least 6 months. These last three bipolar subjects had received neuroleptic medication for previous epi-sodes of bipolar illness but not for the current epi sode. Nine of the schizophrenic subjects were of the undifferentiated type, and 13 were of the paranoid type. Of the paranoid group, four had late-onset schizophrenia. Seven of the 14 patients with bipolar illness were psychotic (i.e., had one or more of the following symptoms: hallucinations, delusions, or thought disorder) at the time of PET scanning. Delu sions and/or hallucinations, when present, were mood congruent in bipolar patients. Patients classi fied as nonpsychotic had none of these symptoms. The mean length of the current episode for the bipo lar patients was 5.4 ± 7.8 months. Additional clinical characteristics and neuropsychological profiles of the schizophrenic subjects are detailed for adult onset (neuroleptic naive only) in Tune et ai. (1993) and for late onset (neuroleptic naive only) in Pearlson et ai. (1993) . The clinical characteristics and symptom profiles of the bipolar subjects are detailed in Pearl son et ai. (1995) . Normal subjects were free of present and past physical or psychiatric disorders and were never exposed to neuroleptics. A summary of the age and gender distribution of the subjects is given in Table 1 . PET and image analysis followed the proce dure previously published (Wong et ai., 1986b (Wong et ai., , 1997 .
For all subjects, regardless of diagnostic group, all specific activities at the time of injection exceeded 1 /-LCi pmol-I, consistent with DTlike receptor occu pancy of less than 5%. Thus, any differences between injected mass of ligand could not confound the recep tor density quantification. (The age difference for schizophrenic patients and matched controls studied pre-and post-1986 was dictated by a shift in our research focus to late-onset schizophrenia and to pa tients who could remain medication free for ex tended periods.)
Statistical analysis for PET studies. To examine the relationship between age and Bmax , simple linear regressions of Bmax versus age were first fitted sepa rately for each of the diagnostic groups (normal controls, schizophrenic patients, psychotic and non psychotic patients with bipolar disease). A quadratic term for age was also tested but was never significant for any subgroup. For the regression of Bmax on age, a combined model across all diagnostic groups was tested for differences between the slopes and inter cepts across these groups. The analysis employed a single-regression model with dummy variables and terms for the interaction of age and group (Klein baum et aI., 1988) . We used backward elimination with a probability limit of p = 0.05 for a variable to remain in the model.
We also compared the simple caudate-cerebellum tissue ratios \ Wong et aI., 1984) among diagnos tic groups with the same regression model as that used for Bmax . The prehaloperidol caudate-cerebel lum ratio at 45 min (R4S) was the dependent vari able.
To examine whether patients studied after 1986 demonstrated Bmax elevation, we performed a regres sion analysis with diagnosis (schizophrenia vs. con trol) and study period (pre-vs. post-1986) as inde pendent variables. The model allowed separate intercepts, one for each diagnostic group and each time period; however, because of sample size limita tions, we assumed that within each diagnostic group the slopes of Bmax versus age were the same for both time periods but that the slopes for each group could differ. In this model, we compared the age-adjusted mean Bmax of the post-1986 control subjects and post-1986 schizophrenic patients. Age was adjusted to 42 years, the overall mean age of both diagnostic groups and both time periods.
We also examined the stability of the receptor mea surements over time. Regression analysis was per formed for the Bmax values of all 24 normal control subjects studied between 1985 and 1992. For this anal ysis, Bmax was the dependent measure, and the date of study, age, and age by date interaction were the predictors. Statistical packages included PC-SAS and PC-CARP, Iowa State University. 
RESULTS
Validation of assumptions
In vitro studies 3.1 ± 0.3 6 1. Partition volume: In vitro the mean partition volumes for [18F]haloperidol were not significantly different among the postmortem tissue from controls, patients with schizophrenia, and patients with bipolar disease. All values approximated 3 ml g-I (Table 1) .
2. Plasma protein binding: The fractions of NMSP and haloperidol that were free in plasma (i.e., not bound to plasma proteins) were not significantly dif ferent between patients and normal volunteers (Ta ble 2).
3. Tracer metabolism: The HPLC retention time was approximately 4 min for [ II C]NMSP and 2.6 min for metabolites (typically, the recovery was of the order of 90%). There was an excellent correlation between modeled and HPLC-measured metabolites, r = 0.99. No significant difference between the kinetic and HPLC metabolite corrections was observed for any diagnostic group (Fig. 2) .
In vivo studies 1. Subject characteristics: Blood pressure, pulse, weight, and nutritional status at the time of the scan were not significantly different between the normal controls and patient groups. Mean ages and sex distri bution for all subjects studied between 1985 and 1991 are described in Table 3 . The table presents the sam ple characteristics separately for subjects studied pre (overlapping Wong et aI., 1986c ) and post-1986.
2, Receptor density: Regression analysis of Bmax values for all normal controls against the date of study revealed no significant effects resulting from the date of study or the interaction between age and [1BF]haloperidol 3.5 ± 0.2 (10) 4.1 ± 0.8 (5) 3.3 ± 0.5 (7) date (p > 0.32), which suggests that no temporal bias occurred in the normal volunteers. The decline of Bmax with age examined in each patient group, includ ing previously studied control subjects, schizophrenic patients, non psychotic patients with bipolar disease, and psychotic patients with bipolar disease, is shown in Fig. 1 . The results of the individual regressions are provided in Table 4 .
When the data from the diagnostic groups were pooled for the regression analysis, a common slope for all four groups indicated a significant change with age of -0.31 ± 0.08 (SEM) pmol g-I yr-I . The non psychotic patients with bipolar disease and the nor mal control subjects had a single intercept (Bo) of 28 ± 4 pmol g-' . The psychotic patients with bipolar disease and the schizophrenic patients shared a single intercept of 44 ± 5 pmol g-I . Thus, when an omnibus significance test was applied, the subjects fell into two groups: one group consisting of psychotic sub jects with a significantly higher intercept but equiva lent slope and a second group consisting of all non psychotic subjects. In all groups, decline with age occurred at the rate of approximately 1 % of Bo per year, indicating that all Drlike receptors have disap peared by the age of 100 years.
A separate test was carried out to determine whether p .. tients with schizophrenia studied after 1986 had significantly elevated values of Bmax relative to normal volunteers studied after 1986. The Bmax estimates were calculated under the assumption that within each diagnostic group, the age decline was the same for pre-and post-1986 subsamples. Backward elimination for the post-1986 group suggested a com- To test for group differences, we pooled the four subject groups for multiple linear regression with the ratio index as the dependent and age and diagnosis as the independent variables. Backward elimination identified a common slope for all groups and indi cated a significant change with age of -0.026 ± 0.005 year-I. The subj ect groups shared a single zero-age intercept (R) of 4.5 ± 0.2. Thus, using the ratio method, there was no significant difference of slope or intercept among any of the patient groups.
DISCUSSION
This study addressed three questions raised by the application to psychosis of a particular solution to a . 1. 8m ., versus age is plotted for normal versus schizophrenic subjects (A) (e), SCZ; (+) NOR, and normal versus bipolar psychotic and bipolar nonpsychotic subjects (8) (e) psychotic bipolar; (0) non psychotic bipolar. The individual linear regression lines are plotted and given in Table 4 . The statistical analysis results are given in Table 4 . quantitative model for receptor binding. The validity of the method's application to normal volunteers was considered in the preceding paper .
Validation of assumptions
The first question considered the validity of the assumptions underlying the Woolf-Hanes plot and the extent to which the consequent procedures biased the results in psychotic patients. The partition of NMSP between brain tissue and blood plasma was comparable to the in vivo partition volume deter mined with PET. The validation revealed no signifi cant difference between the partition volume of pa- tients and normal volunteers. The identification of free fractions of P lC]NMSP in patients and control subjects strengthened the finding of identical parti tion volumes in vitro and in vivo. The metabolism of [11C]NMSP in the circulation was measured by HPLC. The evaluation demon strated excellent agreement with the kinetic assay used previously. Both assays were unbiased across di agnoses.
Effect of age on psychosis
In response to the second question of a decline of the Drlike dopamine receptor density with age, we also demonstrated a decrease in Bmax with age in FIG. 2. Plasma radioactivity concentra tions were corrected for metabolites by two methods. On the abscissa axis are radioactivity measures corrected by high pressure liquid chromatography (HPLC) assay described in the Methods section. On the ordinate axis are the radioactivity measures corrected using the model derived corrections applied to the mea sured total plasma radioactivity for the hu man subjects. Units are in /LCilmi. The subject population consisted of normal controls, schizophrenic patients, and bi polar illness patients. Radioactivity mea sures were obtained throughout the 90-min study. The linear regression is [model corrected plasma (/LCi/ml») = (1.03) [HPLC-corrected plasma (/LCi/ml») -0.01 /LCi/ml, ,.., = 0.98.
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patients with psychiatric disorders. The decline with age was previously demonstrated with the modified Woolf-Hanes plot in normal volunteers (Wong et aI., 1997) . Hess et ai. (1987) suggested such a decline with age in a post-mortem study of schizophrenia. Thus, because of the strong evidence for a decline of Bmax resulting from aging, age correction of Bmax values is necessary for the comparison of neuropsy chiatric patients and control subjects. There was no significant difference between the decline with age for all four diagnostic groups (i.e., normal, schizo phrenia, psychotic, and nonpsychotic bipolar disor der), although the sample size for the latter two groups would need to be enlarged to be more defin itive.
Elevation of Bmax in psychosis
The third question was whether the age correction described above would lead to differences in Bmax for the two psychotic disorders relative to controls. It was recently shown that late-onset schizophrenic patients also revealed elevations in Bmax when calcu lated with [llC]NMSP (Pearlson et aI., 1993) . In the current study, the age correction of Bmax revealed elevations of dopamine D2-like receptors in a psy chotic illness other than schizophrenia. Thus, the re ceptor densi� was elevated in psychotic patients with bipolar disorder compared with nonpsychotic pa tients who have the same disease. The present finding suggests that psychosis, whether in early or late-onset schizophrenia or in bipolar illness, is associated with the Bmax elevation of Drlike receptors (Wong et aI., 1989) . This finding is consistent with the positive cor relation observed in bipolar patients between their Bmax for Drlike receptors and their quantitative psy chosis score (mini-present state exam) (Pearlson et aI., 1995) .
The finding of normal Bmax estimates in nonpsy chotic patients with bipolar disorder argues against a systematic error for increased D2-like receptors in patients with psychotic disorders. This finding sug gests, therefore, a link between psychosis and ele-vated Drlike receptors. This link, that not only recep tors of dopamine but also the dopamine synthesizing enzyme, dopa decarboxylase, is elevated in diseases with psychosis but normal in healthy volunteers and patients without psychosis, was recently suggested by the findings of Reith et ai. (1994 ) . Dopamine D2 receptor Bmax estimates were not significantly differ ent in psychotic patients with bipolar disease and in drug-naive patients with schizophrenia, suggesting that D2-like dopamine neuroreceptors may play a role in all psychiatric disorders that have prominent psychotic symptoms in common.
The subset of schizophrenic patients studied since 1986 had significant elevations of Bmax when individ ual values were adjusted for age. The smaller increase seen in this study compared with the 225% increase observed previously (Wong et aI., 1986c ) may relate to differences in gender, age, and clinical characteris tics of the more recently studied sample (Tune et aI., 1993) . This finding reflects differences in recruitment as described in Methods and also could explain in part the alleged lack of difference observed by Nord strom et ai. (1995) using [llC]NMSP; however, evi dence of significant elevation of Bmax in schizophreni form men has raised questions about the conclusions of that study (Gjedde et aI., 1995) .
From the review of the literature, two questions arise: The first question is, Why are increases of Bmax not reflected in calculations of the caudate cerebellum ratio? Most studies failed to reveal eleva tions in dopamine receptors with the simple caudate or putamen-cerebellum ratio as a means of quantify ing dopamine receptor density. A significant differ ence was not observed in the present study for the calculated ratio at 45 min (R4S)' The reason is the following: R45 is a mixed function of the rate constants k2 and k3, when k3 is low; however, for high k3, R45 is a function primarily of k2, which in turn is related to blood-brain permeability and blood flow and not to dopamine Bmax. A kinetic description of the ratio (e.g., R4S) is given in the Appendix. Figure 3 illus trates the dependence of R45 on the magnitude of k3 relative to k2 at values of p ranging from 1 to 3. This correlation is weak for higher values of p. Thus, the dependence of R45 on k3 is not linearly proportional to the value of k3 and cannot be easily distinguished between subjects such as schizophrenic patients with high k3 values and subjects with low k3 values. Fur thermore, Fig. 3 shows that R45 is a multivalued func tion of k3• This may explain in part why two popula tions with different values of Bmax may have the same value of R45. Conversely, R45 detects falls with age because both k2 and k3 fall with age. Thus, ratio indices are not reliable measures of ligand binding for tracers like NMSP that do not reach "pseudo equilibrium" during the imaging time.
The second question is, Why is no elevation gener ally observed with [11C]raclopride? One possibility relates to D4 receptors. Dopamine Dz-like receptors include DZ-D4 receptors of uncertain function and location. Because [11C]NMSP has a high and [llC]raclopride a negligible affinity for the D4 recep tors, it has been suggested that the increased receptor densities observed with NMSP are due to elevated D4 receptors undetected by [11C]raclopride (Lathi et ai., 1993; Seeman et ai., 1993) . There is an increasing general belief that the D2 receptors are presynapti cally located on neuronal terminals other than the dopaminerg\c terminals themselves, whereas the D3 receptors are the Dz-like autoreceptors on dopamin ergic terminals. D4 receptors have been found in post mortem striatum in which the difference between the densities of Dz-like receptors recorded with NMSP and raclopride is greatest. (D4 receptors are sparse in normal subjects.) Another neuroreceptor ligand with considerable affinity for the D4 receptor is clo zapine, a promising atypical neuroleptic. A sixfold elevation of D4 receptors in the striatum of schizo phrenic patients has been reported (Seeman et ai., 1993) . The in vitro D4 elevation was calculated from a 62% increase of [ 3 H]emonapride binding in schizo phrenic brain tissue. Although this finding and the presence of a true D4 receptor in striatum are contro versial (Reynolds and Mason, 1994; Seeman et ai., 1995) , these findings agree in principle with the ap parent "D4-like" results of other groups (Owen et ai., 1978; Lee and Seeman, 1980; Seeman et ai., 1984 Seeman et ai., , 1987a Seeman et ai., ,b, 1993 Mita et ai., 1986; Murray et ai., 1995) . It was recently suggested that the actual D4 receptor (which has been cloned and for which mR NA can be identified) is actually distributed in cortical re gions, such as hippocampus, entorhinal, and cingulate cortex, and is in fact present in very low levels in the caudate and putamen (Lahti et ai., 1996) . Thus, the elevations observed here and elsewhere (see Table  6 ) are henceforth referred to as "D4-like" (Seeman et ai., 1996) , which seems justified in that the literature J Cereb Blood Flow Metab. Vol. 17. No.3, 1997 bears out patient differences that still seem to be ligand dependent.
We have tabulated the current and previous clini cal findings in Table 5 . The data presented there reveals a � 100% increase in [llC] NMSP binding in the caudate nucleus of all drug-naive schizophrenic subjects. Even more striking is the result when data from all psychotic patients are included, as permitted by statistical analysis, which shows no signficance in the age decline of Bmax between these groups. In this case, the increase in psychotic subjcts is �60%, which is remarkably consistent with data from other work ers. The exception to this observed Bmax elevation in psychosis is in the in vivo ratio studies, in which quantification maybe insufficient given the nonequi librium nature of the tracer and the lack of kinetic analysis as explained above (Farde et ai., 1990; How ard et ai., 1993; Martinot et ai., 1991; Konig et ai., 1991) . The degree to which the D4 receptors actually contribute to the elevations seen in this report re quires more specific experiments, aided by specific D4 ligands tested in psychotic patients. An alternative hypothesis to these apparent striatal differences may reside in the hypothesis that raclopride binds to mo nomers and dimers in different proportions and that the monomeric contribution is significantly elevated in psychosis. (Seeman et ai., 1996) Regardless of the mechanism, an NMSP-raclopride discrepancy seems to be apparent, as seen in Table 5 , although the mech anism is still unclear.
Another possibility relates to the effect of greater intrasynaptic dopamine release in schizophrenia. This possibility was already suggested by Laruelle et ai. (1995) , who used [llC]raclopride. The effect of this dopamine release contributing to an apparent Bmax reduction was also suggested (Wong et ai., 1995) . This effect may be greater with raclopride than with NMSP (Young et ai., 1991; Seeman et ai., 1989) .
Finally, patient heterogeneity is always an import ant consideration in discrepant studies (Andreasen et ai., 1988) . The patients from this study may differ substantially from those in whom no significant differ ences were observed, especially those in Sweden. Dif ferences in age of onset, duration of illness, and oth ers could contribute importantly to the differences in the outcomes of the various studies (T une et ai., 1993) .
In summary, the most important findings of this study are the evidence of declining receptor density with age in several forms of psychosis and the evi dence of similar declines with age in the elevations of Dz-like receptors in two different psychotic disorders. Using a validated method of determining Bmax, these findings suggest that psychosis is associated with ele vations in Dz-like receptors in general, not only in schizophrenia. This suggestion has important impli- 
FIG. 3. A simulated plot of R45 versus kJk2. Eq. 4 is plotted for values of kJk2 ranging from 0 to 10 for typical values of k3 with a fixed value of k2 = 0.05 min-1; p = 1, 2, and 3; 0 = 90 min. The graph illustrates the lack of sensitivity of R45 for wide ranges of k3 (hence 8max) as well as the possibil ity for two values of kJ k2 for a given value of R45 (see Discussion). Ordinate R45 (ratio), abscissa kJ k2 (m in -11m in -1).
( 1982) for the slightly different situation of the ratio of two brain regions by Patlak and Blasberg ( 1985) and also by Wong et al. ( 1986a) . In the present de scription, we have directly compared the ratio method to the kinetic method and revealed its impli cations for application to disease states. The ratio at 45 min, R45, was evaluated to illustrate the relationship between R45 and k3 ( see Fig. 3 ). Com putationally, R45 is determined mainly by the tracer amount in the brain in the region of interest ( e.g., caudate) normalized to the nonspecifically bound tracer in cerebellum. The contribution to R45 of the region of interest consists of tracer in the free pool (M f ), the rapidly equilibrating pool (Mr), and the bound pool (Mb), as tracer in the blood volume makes a relatively small contribution.
Whether R45 rises or falls with k3/k2 ( for fixed k2) depends on the relative magnitude of the first term, which rises monotonically, and the second term, which falls monotonically with k3/k2 when k2 has a fixed magnitude. The second term has important con sequences for the ratio between two regions when the region of interest has both a higher partition volume and significant binding. The second term in cludes a term for the rapidly equilibrating but non specific binding in the region of interest (p) and a term that depends on the dynamics of the binding process, [k2/(k2 + k3)] 2 . In the absence of binding (k3 = 0), p prevails and forces the ratio to assume a high value. In the presence of binding, the value of [k2/(k2 + k3)F causes the second term to decline because less tracer is kept in the precursor pool in the presence of binding. The effect of p, equal to the k5/k6 ratio of the additional binding compartment (Mr) assumed to be in rapid equilibrium with the free tracer pool, is to magnify the total amount of tracer that is not bound to the receptors of interest ( equal to the sum of free and nonspecifically bound tracer) by the factor 1 + p, which is itself equal to f�efjJ�OI, the ratio between the free fraction in the reference region (f� ef ) and the free fraction in the region of interest (f�0I). Thus, at low k3 values, the amount of tracer that can pass into the bound com partment is relatively small, and most of the tracer passes back into the plasma compartment upon the onset of transient equilibrium, when k2 � k3• This causes the R45 value (sum of nonbound and bound pools divided by the cerebellar nonbound pool) to decline initially, as seen in Fig. 3 . For each value of p, a minimum of R45 is achieved at different k31kz values. This minimum value of R45 occurs when the decline of tracer in the nonbound pool no longer exceeds the transfer of tracer to the binding pool, and k31kz rises, that is, when k3 eventually becomes so high that the quantity bound overcomes the de cline of tracer in the nonbound pools. Thereafter, R45 rises m onotonically with increasing k3lkz. The balance between the two processes, �nd hence the point of minimum R45, depends on the relative mag nitudes of p and k3• A minimum occurs at 
For the special case of small p and specific values of kz in the binding region of interest (e.g., caudate), R45 rises monotonically for all values of k3. An exam ple is shown in Fig. 3, where p :s 1 and kz = 0.05. In general, no minimum occurs when 2(1 + p) :S kz e.
R45 would then be monotonically increasing for all nonzero k3• Without a considerable number of bind ing sites in Mr, the magnification of the nonbound pool does not occur to the same degree, and the reduction of tracer in the precursor pool is countered by the tracer in the binding compartment. Hence, no actual fall in R45 occurs.
